{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:47:31Z","timestamp":1792172851293,"version":"4.4.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2019,11,10]],"date-time":"2019-11-10T00:00:00Z","timestamp":1573344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01NS102669"],"award-info":[{"award-number":["R01NS102669"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01NS107833"],"award-info":[{"award-number":["R01NS107833"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Northwestern SPORE in Brain Cancer","award":["P50CA221747"],"award-info":[{"award-number":["P50CA221747"]}]},{"name":"Lou Malnati Cancer Research Foundation"},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","award":["2015215"],"award-info":[{"award-number":["2015215"]}],"id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kathy and Mark Frederickson"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Progress in extending the survival of glioblastoma (GBM) patients has been slow. A better understanding of why patient survival remains poor is critical to developing new strategies. Postmortem studies on GBM can shed light on why patients are dying.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The brains of 33 GBM patients were autopsied and examined for gross and microscopic abnormalities. Clinical-pathologic correlations were accomplished through detailed chart reviews. Data were compared with older published autopsy GBM studies that predated newer treatment strategies, such as more extensive surgical resection and adjuvant temozolomide.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In older GBM autopsy series, mass effect was observed in 72% of brains, with herniation in 50% of all cases. Infiltration of tumor into the brainstem was noted in only 21% of those older cases. In the current series, only 10 of 33 (30%) GBMs showed mass effect (P = 0.0003), and only 1 (3%) showed herniation (P &amp;lt; 0.0001). However, extensive GBM infiltration of the brainstem was present in 22 cases (67%, P &amp;lt; 0.0001), with accompanying destruction of the pons and white matter tracts. There was a direct correlation between longer median patient survival and the presence of brainstem infiltration (16.1 mo in brainstem-invaded cases vs 9.0 mo in cases lacking extensive brainstem involvement; P = 0.0003).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>With improving care, severe mass effect appears to be less common in GBM patients today, whereas dissemination, including life-threatening brainstem invasion, is now more pronounced. This has major implications regarding preclinical GBM models, as well as the design of clinical trials aimed at further improving patient survival.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/neuonc\/noz216","type":"journal-article","created":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T04:28:35Z","timestamp":1573100915000},"page":"470-479","source":"Crossref","is-referenced-by-count":97,"title":["Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas"],"prefix":"10.1093","volume":"22","author":[{"given":"Michael R","family":"Drumm","sequence":"first","affiliation":[{"name":"Department of Neurological Surgery, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan S","family":"Dixit","sequence":"first","affiliation":[{"name":"Department of Neurology, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Grimm","sequence":"first","affiliation":[{"name":"Department of Neurology, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Kumthekar","sequence":"first","affiliation":[{"name":"Department of Neurology, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimas V","family":"Lukas","sequence":"first","affiliation":[{"name":"Department of Neurology, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J","family":"Raizer","sequence":"first","affiliation":[{"name":"Department of Neurology, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Stupp","sequence":"first","affiliation":[{"name":"Department of Neurology, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan G","family":"Chheda","sequence":"first","affiliation":[{"name":"Department of Medicine, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwok-Ling","family":"Kam","sequence":"first","affiliation":[{"name":"Department of Pathology, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"McCord","sequence":"first","affiliation":[{"name":"Department of Pathology, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Sachdev","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Kruser","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Steffens","sequence":"first","affiliation":[{"name":"Department of Neurological Surgery, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Javier","sequence":"first","affiliation":[{"name":"Department of Neurological Surgery, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"McCortney","sequence":"first","affiliation":[{"name":"Department of Neurological Surgery, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Horbinski","sequence":"first","affiliation":[{"name":"Department of Neurological Surgery, Northwestern University, Chicago, Illinois"},{"name":"Department of Pathology, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,11,10]]},"reference":[{"issue":"10","key":"2020041508355433100_CIT0001","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med."},{"issue":"10","key":"2020041508355433100_CIT0002","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med."},{"issue":"14","key":"2020041508355433100_CIT0003","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","article-title":"NovoTTF-100A versus physician\u2019s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality","volume":"48","author":"Stupp","year":"2012","journal-title":"Eur J Cancer."},{"issue":"23","key":"2020041508355433100_CIT0004","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA."},{"issue":"12","key":"2020041508355433100_CIT0005","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1002\/1097-0142(19831215)52:12<2320::AID-CNCR2820521227>3.0.CO;2-N","article-title":"Correlations between cytologic composition and biologic behavior in the glioblastoma multiforme. A postmortem study of 50 cases","volume":"52","author":"Giangaspero","year":"1983","journal-title":"Cancer."},{"issue":"2","key":"2020041508355433100_CIT0006","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF00146880","article-title":"The cause of death in patients with glioblastoma is multifactorial: clinical factors and autopsy findings in 117 cases of supratentorial glioblastoma in adults","volume":"10","author":"Silbergeld","year":"1991","journal-title":"J Neurooncol."},{"issue":"4","key":"2020041508355433100_CIT0007","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1227\/00006123-199010000-00002","article-title":"Brain stem and spinal metastases of supratentorial glioblastoma multiforme: a clinical series","volume":"27","author":"Vertosick","year":"1990","journal-title":"Neurosurgery"},{"issue":"6","key":"2020041508355433100_CIT0008","doi-asserted-by":"crossref","first-page":"330","DOI":"10.5414\/NP300882","article-title":"Massive dissemination of adult glioblastomas","volume":"34","author":"Willard","year":"2015","journal-title":"Clin Neuropathol"},{"issue":"11","key":"2020041508355433100_CIT0009","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/neuonc\/nop045","article-title":"Symptoms and problems in the end-of-life phase of high-grade glioma patients","volume":"12","author":"Sizoo","year":"2010","journal-title":"Neuro Oncol."},{"issue":"3","key":"2020041508355433100_CIT0010","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/neuonc\/nov289","article-title":"Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors","volume":"18","author":"Nikiforova","year":"2016","journal-title":"Neuro Oncol."},{"issue":"4","key":"2020041508355433100_CIT0011","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1227\/00006123-198910000-00005","article-title":"Cerebral glioblastoma with cerebrospinal fluid dissemination: a clinicopathological study of 14 cases examined by complete autopsy","volume":"25","author":"Onda","year":"1989","journal-title":"Neurosurgery."},{"issue":"4","key":"2020041508355433100_CIT0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4322\/acr.2017.036","article-title":"Declining rate of autopsies: implications for anatomic pathology residents","volume":"7","author":"Hamza","year":"2017","journal-title":"Autops Case Rep."},{"issue":"3","key":"2020041508355433100_CIT0013","first-page":"80","article-title":"Attitudes toward the autopsy\u2014an 8-state survey","volume":"8","author":"Nemetz","year":"2006","journal-title":"MedGenMed."},{"issue":"4","key":"2020041508355433100_CIT0014","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/1097-0142(197910)44:4<1256::AID-CNCR2820440415>3.0.CO;2-T","article-title":"The morphologic effects of radiation administered therapeutically for intracranial gliomas: a postmortem study of 25 cases","volume":"44","author":"Burger","year":"1979","journal-title":"Cancer."},{"issue":"4","key":"2020041508355433100_CIT0015","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/jmri.22330","article-title":"Diffusion tensor tractography of the human brain cortico-ponto-cerebellar pathways: a quantitative preliminary study","volume":"32","author":"Kamali","year":"2010","journal-title":"J Magn Reson Imaging."},{"key":"2020041508355433100_CIT0016","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1748-717X-8-97","article-title":"Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution","volume":"8","author":"Ogura","year":"2013","journal-title":"Radiat Oncol"},{"issue":"1","key":"2020041508355433100_CIT0017","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11060-013-1279-z","article-title":"Factors associated with a higher rate of distant failure after primary treatment for glioblastoma","volume":"116","author":"Tejada","year":"2014","journal-title":"J Neurooncol"},{"issue":"6","key":"2020041508355433100_CIT0018","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00401-016-1620-7","article-title":"Mutant IDH1 and thrombosis in gliomas","volume":"132","author":"Unruh","year":"2016","journal-title":"Acta Neuropathol."},{"issue":"17","key":"2020041508355433100_CIT0019","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1158\/1078-0432.CCR-17-1846","article-title":"T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma","volume":"24","author":"Woroniecka","year":"2018","journal-title":"Clin Cancer Res."},{"issue":"9","key":"2020041508355433100_CIT0020","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41591-018-0135-2","article-title":"Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors","volume":"24","author":"Chongsathidkiet","year":"2018","journal-title":"Nat Med."},{"issue":"3","key":"2020041508355433100_CIT0021","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s11060-014-1592-1","article-title":"Leptomeningeal dissemination in glioblastoma: an inspection of risk factors, treatment, and outcomes at a single institution","volume":"120","author":"Mandel","year":"2014","journal-title":"J Neurooncol"},{"key":"2020041508355433100_CIT0022","author":"Noone","year":"2018"},{"issue":"8","key":"2020041508355433100_CIT0023","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N Engl J Med."},{"issue":"8","key":"2020041508355433100_CIT0024","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med."},{"issue":"20","key":"2020041508355433100_CIT0025","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","article-title":"Lomustine and bevacizumab in progressive glioblastoma","volume":"377","author":"Wick","year":"2017","journal-title":"N Engl J Med."},{"issue":"3","key":"2020041508355433100_CIT0026","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/neuonc\/nop027","article-title":"Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice","volume":"12","author":"de Groot","year":"2010","journal-title":"Neuro Oncol."},{"issue":"1","key":"2020041508355433100_CIT0027","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccr.2012.05.037","article-title":"VEGF inhibits tumor cell invasion and mesenchymal transition through a MET\/VEGFR2 complex","volume":"22","author":"Lu","year":"2012","journal-title":"Cancer Cell."},{"issue":"6","key":"2020041508355433100_CIT0028","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/0360-3016(89)90548-8","article-title":"Radiation therapy treatment planning in supratentorial glioblastoma multiforme: an analysis based on post mortem topographic anatomy with CT correlations","volume":"17","author":"Halperin","year":"1989","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"6","key":"2020041508355433100_CIT0029","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3171\/jns.1987.66.6.0865","article-title":"Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms","volume":"66","author":"Kelly","year":"1987","journal-title":"J Neurosurg."},{"issue":"1","key":"2020041508355433100_CIT0030","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ijrobp.2006.12.009","article-title":"Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma","volume":"68","author":"Chang","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"5","key":"2020041508355433100_CIT0031","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00401-013-1106-9","article-title":"What do we know about IDH1\/2 mutations so far, and how do we use it?","volume":"125","author":"Horbinski","year":"2013","journal-title":"Acta Neuropathol."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noz216\/32517384\/noz216.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/22\/4\/470\/33047202\/noz216.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/22\/4\/470\/33047202\/noz216.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T12:37:15Z","timestamp":1586954235000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/22\/4\/470\/5618827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,10]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,11,10]]},"published-print":{"date-parts":[[2020,4,15]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noz216","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,4]]},"published":{"date-parts":[[2019,11,10]]}}}